AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00117377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % bid
Study NCT00117377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo application bid
Study NCT02408419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is injected proximally to anesthetize the obturator nerve
Study NCT02408419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is injected as a placebo
Study NCT03670186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
Study NCT04494321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid
Study NCT04494321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled corticosteroid
Study NCT04494321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study NCT00827307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
Study NCT01337310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
Study NCT03688763 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
Study NCT04554186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral block
Description: Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
Study NCT04554186 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Place a fentanyl patch 50 microgram
Study NCT02698345 — intervention group
Intervention type: DEVICE
Intervention: drug-eluting balloon (In.PACT Admiral, Medtronic)
Study NCT04561115 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gamunex-C
Description: Intravenous infusion.
Study NCT04561115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG-PEG
Description: Intravenous infusion.
Study NCT02261181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XONRID
Description: The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
Study NCT00945438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine 2009-2010 formulation
Description: 0.1 mL, Intradermal
Study NCT00945438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine 2009-2010 formulation
Description: 0.5 mL, Intradermal
Study NCT04305535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptidic+Probiotic
Description: Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1
Study NCT04305535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptidic+Placebo
Description: Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
Study NCT04305535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polymeric+Placebo
Description: Polymeric oral nutritional supplement and a placebo
Study NCT00784095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life completion and preparation
Description: Subjects will discuss life review, issues of forgiveness and heritage and legacy.
Study NCT00784095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Subjects will listen to a non-guided relaxation CD.
Study NCT04491838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single subcutaneous (SC) injection
Study NCT04303624 — intervention group
Intervention type: OTHER
Intervention: Health sciences survey
Description: Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
Study NCT03220529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner
Study NCT01310855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cediranib maleate
Study NCT01310855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cediranib maleate
Study NCT00965510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care coordination
Description: patients receive care coordination to improve their type II diabetes
Study NCT01310855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Study NCT01310855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02875925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM
Description: Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
Study NCT03175432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03175432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00640341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision Contact Lens
Description: contact lens for daily wear
Study NCT03175432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03175432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04536831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D will be given to group A selected by Lottery method
Study NCT04536831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Vitamin D will be given to group B slected by Lottery method
Study NCT00346944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of dental amalgam restorations
Description: Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
Study NCT01763671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01763671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01763671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01354067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
Study NCT01354067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-repetitive single limb training
Description: The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
Study NCT00640341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Contact Lens
Description: contact lens for daily wear
Study NCT00640341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2Optix Contact lens
Description: contact lens for daily wear
Study NCT06353724 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning
Description: Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment.
Study NCT03464058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules
Study NCT00573196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far infrared
Description: Far infrared radiation (5μm to 15μm wavelength)
Study NCT00048061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate [Bonviva/Boniva]
Description: 2.5mg po daily
Study NCT06353724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital positioning stent
Description: Digital positioning stent
Study NCT06111534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
Study NCT01513044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
Study NCT01513044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 250 mg capsules of Roche Laboratories Inc.
Study NCT00048061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 100mg po monthly on a single day
Study NCT00048061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 100mg po monthly over 2 consecutive days
Study NCT00048061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 150mg po monthly
Study NCT00048061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 500 mg/day
Study NCT03397667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABC ANSWERS
Description: Primary Care plus ABC ANSWERS
Study NCT00048061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 500 mg/day
Study NCT00048061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU/day
Study NCT00048061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU/day
Study NCT03560830 — intervention group
Intervention type: OTHER
Intervention: 2 submaximal exercise stress tests
Study NCT03397667 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Primary Care as usual
Study NCT05998980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Componeer prefabricated veneers
Description: Individual Randomized Clinical Trial
Study NCT01902251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide tablet
Description: Oral
Study NCT01902251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide capsule
Description: Oral
Study NCT01346917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
Study NCT01346917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
Study NCT04005170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
Study NCT04005170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Cisplatin
Description: Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
Study NCT04005170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
Study NCT01292785 — intervention group
Intervention type: DRUG
Intervention: Hormones
Description: FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is > 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss.
Study NCT05959603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
Study NCT05998980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Essentia resin composite veneers
Description: Individual Randomized Clinical Trial
Study NCT04494321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study NCT03878082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol 1g
Description: pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
Study NCT03878082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol 2g
Description: pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
Study NCT03878082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IVPCA
Description: pain control with IVPCA
Study NCT03878082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVPCA
Description: pain control with IVPCA
Study NCT02445443 — intervention group
Intervention type: DEVICE
Intervention: LEGION Hinge Knee System
Description: All enrolled/treated subjects will receive the LEGION Hinge Knee System.
Study NCT03353389 — intervention group
Intervention type: OTHER
Intervention: No AKI
Description: Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
Study NCT03353389 — intervention group
Intervention type: OTHER
Intervention: CA-AKI
Description: CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown.
Study NCT03353389 — intervention group
Intervention type: OTHER
Intervention: HA-AKI
Description: HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown.
Study NCT04640181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin While hospitalized only.
Study NCT04640181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
Study NCT01362751 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This study is an observational cohort study > no interventions
Study NCT00107952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day IV for up to 21 days.
Study NCT00107952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV q 12 hrs for up to 21 days
Study NCT03792243 — intervention group
Intervention type: PROCEDURE
Intervention: Complication
Description: Readmission, reoperation
Study NCT02008578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous hyperimmune immunoglobulin (Flu-IVIG)
Study NCT02008578 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01296243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.